MedPath
HSA Approval

EYBELIS-S OPHTHALMIC SOLUTION 0.002%w/v

SIN16951P

EYBELIS-S OPHTHALMIC SOLUTION 0.002%w/v

EYBELIS-S OPHTHALMIC SOLUTION 0.002%w/v

February 19, 2024

SANTEN PHARMACEUTICAL ASIA PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSANTEN PHARMACEUTICAL ASIA PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

SOLUTION, STERILE

OPHTHALMIC

Medical Information

S01EX06

omidenepag

Manufacturer Information

SANTEN PHARMACEUTICAL ASIA PTE. LTD.

Santen Pharmaceutical Co., Ltd. Noto Plant

Active Ingredients

Omidenepag isopropyl

0.02 mg/mL

Omidenepag isopropyl

Documents

Package Inserts

Eybelis-S PI.pdf

Approved: February 19, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

EYBELIS-S OPHTHALMIC SOLUTION 0.002%w/v - HSA Approval | MedPath